Volume 27, Number 6—June 2021
Research
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA
Mariana M. Lanata1, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, and Amy Leber
Table 1
Patient demographics and clinical characteristics of children infected with macrolide-sensitive and macrolide-resistant strains of Mycoplasma pneumoniae, Ohio, USA, 2015–2019*
| Characteristic | MRMp, n = 12 | MSMp, n = 332 | p value |
|---|---|---|---|
| Sex | 0.9046 | ||
| M | 7 (55) | 175 (53) | |
| F |
5 (45) |
157 (47) |
|
| Year | 0.6508 | ||
| 2015 | 4 (33) | 146 (44) | |
| 2016 | 1 (8) | 51 (15) | |
| 2017 | 2 (17) | 52 (16) | |
| 2018 | 5 (42) | 73 (22) | |
| 2019 |
0 |
10 (3) |
|
| Age, y, mean (SD) |
9.13 (3.74) |
8.73 (4.62) |
0.7683 |
| Previous visits | |||
| Any previous visits | 8 (67) | 188 (57) | 0.4901 |
| No. previous visits, median (IQR) |
1.5 (1–2) |
1 (1–2) |
0.3491 |
| Underlying conditions | 6 (50) | 139 (42) | 0.5752 |
| Chronic immunosuppression | 1 (8) | 5 (2) | 0.1392 |
| Up to date in vaccines |
12 (100) |
316 (97) |
>0.9999 |
| Inpatient | 6 (50) | 130 (39) | 0.551 |
| Median duration of hospitalization, d (IQR) |
8 (6–10) |
2 (1.5–3) |
0.0132 |
| PICU | 3 (25) | 21 (6) | 0.0433 |
| Median duration of PICU stay, d (IQR) |
2 (1–8) |
2 (1.5–5) |
0.8596 |
| Hypoxemia | 3 (25) | 73 (23) | >0.9999 |
| Median duration of O2 support, d (IQR) | 4 (1–8.5) | 1 (0.5–2) | 0.1302 |
| Mechanical ventilation |
1 (33) |
6 (8) |
0.2487 |
| Median duration of symptoms, d (IQR) |
7 (6.5–13) |
7 (5–10) |
0.3324 |
| Fever | 11 (92) | 271 (81) | 0.7024 |
| Median duration of fever, d (IQR) | 4 (2–7) | 4 (2–7) | 0.984 |
| Median maximum temperature, °C (IQR) |
38.4 (38.1–39.4) |
39.1 (38.4–39.7) |
0.0415 |
| Fatigue | 5 (42) | 91 (27) | 0.3298 |
| Decreased appetite/oral food intake | 4 (33) | 125 (38) | >0.9999 |
| Decreased urine output | 0 | 22 (7) | >0.9999 |
| Cough | 12 (100) | 320 (96) | >0.9999 |
| Shortness of breath/respiratory distress | 5 (42) | 91 (27) | 0.3268 |
| Sore throat | 0 | 67 (20) | 0.1332 |
| CNS manifestation | 2 (17) | 10 (3) | 0.0607 |
| Nausea/vomiting | 1 (8) | 55 (17) | 0.6987 |
| Diarrhea | 1 (8) | 30 (9) | >0.9999 |
| Rash | 0 | 25 (7.5) | >0.9999 |
*Values are no. (%) except as indicated. Bold type indicates statistical significance. CNS, central nervous system; IQR, interquartile range; MRMp, macrolide-resistant Mycoplasma pneumoniae; MSMp, macrolide-sensitive Mycoplasma pneumoniae; PICU, pediatric intensive care unit.
1Current affiliation: Marshall University, Huntington, West Virginia, USA.
Page created: March 30, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.